Serum osteocalcin and urinary crosslaps are suitable markers of bone turnover in response to short-term hormone replacement therapy

References

• Bjarnason NH, Hassager C, Christiansen C. Postmenopausal bone remodelling and hormone replacement. Climacteric 1998; 1: 72–9
   PubMedGoogle Scholar
• Kiel DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. N Engl J Med 1987; 317: 169–74
   PubMed Web of Science ®Google Scholar
• Slemenda C, Hui SL, Longcope C, et al. Sex steroids and bone mass: a study of changes about the time of menopause. J Clin Invest 1987; 80: 1261–9
   PubMed Web of Science ®Google Scholar
• Chem JT, Hosoda K, Hasumi K, et al. Serum N-terminal osteocalcin is a good indicator for estimating responders to hormone replacement therapy in postmenopausal women. J Bone Miner Res 1996; 11: 1784–92
   PubMedGoogle Scholar
• Garnero P, Gineyts E, Arbault P, et al. Different effects of bisphosphonate and estrogen therapy on free and peptide bound bone cross-links excretion. J Bone Miner Res 1995; 10: 641–9
   PubMed Web of Science ®Google Scholar
• Garnero P, Grimaux M, Demiaux B, et al. Measurement of serum osteocalcin with a human specific two-site-radioimmunoassay. J Bone Miner Res 1992; 7: 1389–97
   PubMed Web of Science ®Google Scholar
• Garnero P, Shih WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in later postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693–700
   PubMed Web of Science ®Google Scholar
• Garnero P, Sornay-Rendu E, Delmas PD. Decreased bone turnover in oral contraceptive users. Bone 1995; 16: 499–503
   PubMed Web of Science ®Google Scholar
• Seibel MJ. Hydroxy-pyridinium ‘Crosslinks’ im Urin als spezifischer Marker der Knochen-resorption bei metabolischen Knochenerkrankungen. Klin Lab 1992; 39: 642–3
   Google Scholar
• Uebelhart D, Gineyts E, Demans PD. Urinary excretion of pyridinium cross-links: a new marker of bone resorption in metabolic disease. Bone Miner 1990; 8: 87–96
   PubMedGoogle Scholar
• Bonde M, Quist P, Fledelius C, et al. Immunoassay for quantifying type I collagen degreadation products in urine evaluated. Clin Chem 1994; 40: 2022–5
   PubMed Web of Science ®Google Scholar
• Bonde M, Quist P, Fledelius C, et al. Applictions of an enzyme immunoassay for a new marker of bone resorption (crosslaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995; 80: 864–8
   PubMed Web of Science ®Google Scholar
• Prestwood KM, Pilbeam CC, Burleson JA, et al. The short term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 1994; 79: 366–71
   PubMed Web of Science ®Google Scholar
• Marabini R, Sitori P, Chionna R, et al. Galactosyl-hydroxylysine and pyridinium cross links in monitoring the bone response to hormone replacement therapy. J Endocrinol Invest 1996; 9: 154–8
   Google Scholar
• Schlemmer A, Hassager C, Delmas P, et al. Urinary excretion of pyridinium cross-links in healthy women; the long term effects of menopause and oestrogen/progesterone therapy. Clin Endocrinol 1994; 40: 777–82
   PubMed Web of Science ®Google Scholar
• Schlemmer A, Ravn P, Hassager C, et al. Morning or evening administration of nasal calcitonin? Effects on biochemical markers of bone turnover. Bone 1997; 20: 63–7
   PubMed Web of Science ®Google Scholar
• Bjarnason NH, Bjarnason K, Hassager C, et al. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone 1997; 20: 151–5
   PubMed Web of Science ®Google Scholar
• Hassager C, Fabbri-Mabelli G, Christiansen C. The effect of the menopause and hormone replacement therapy on serum carboxyterminal propeptide of type 1 collagen. Osteoporosis Int 1993; 3: 50–2
   PubMed Web of Science ®Google Scholar
• Peichl P, Griesmacher A, Pointinger P, et al. Association between female sex hormones and biochemical markers of bone turnover in peri- and postmenopausal women. Calcif Tissue Int 1998; 62: 388–94
   PubMedGoogle Scholar
• Schneider P, Butz S, Allolio B, et al. Multicenter German reference data base for peripheral quantitative computer tomography. Technology and Health Care 1995; 3: 69–73
   PubMedGoogle Scholar
• Aoshima H, Kushida K, Takahashi M, et al. Circadian variation of urinary type I collaged crosslinked C-telopeptide and free and peptide-bound forms of pyridinium crosslinks. Bone 1998; 22: 73–8
   PubMed Web of Science ®Google Scholar
• Zaninotto M, Bernardi D, Ujka F, et al. A proposal for standardizing urine collections for bone resorption markers measurement. J Clin Lab Invest 1998; 12: 145–9
   Google Scholar
• Ebeling PR, Atley LM, Guthrie JR, et al. Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab 1996; 81: 3366–71
   PubMed Web of Science ®Google Scholar
• Gertz BJ, Shao P, Hanson DA, et al. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 1994; 9: 135–42
   PubMed Web of Science ®Google Scholar
• Christiansen C, Riis BJ, Rodbro P. Screening procedure for women at risk of developing postmenopausal osteoporosis. Osteoporosis Int 1990; 1: 35–40
   PubMedGoogle Scholar
• Hansen MA, Overgaard K, Riis BJ, et al. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 years study. Br Med J 1991; 303: 961–4
   PubMed Web of Science ®Google Scholar
• Uebelhart D, Schlemmer A, Johansen JS, et al. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross links. J Clin Endocrinol Metab 1991; 72: 367–73
   PubMed Web of Science ®Google Scholar
• Garnero P, Gineyts E, Riou JP, et al. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J. Clin Endocrinol Metab 1994; 79: 780–5
   PubMed Web of Science ®Google Scholar
• Delmas PD. Biochemical markers of bone turnover. J Bone Miner Res 1993; 8(Suppl 2)549–549
   Google Scholar
• Markus R, Holloway L, Wells B, et al. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the postmenopausal estrogen/progestin interventions (PEPI) trial 1999. J Bone Miner Res 1999; 14(9)1583–95
   PubMedGoogle Scholar
• Peichl P, Rintelen B, Kumpan W, et al. Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent salmon nasal calcitonin spray. Gynecol Endocrinol 1999; 13: 7–14
   PubMed Web of Science ®Google Scholar